

Jan Å-stergren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/323536/publications.pdf>

Version: 2024-02-01

69
papers

19,999
citations

126901

33
h-index

95259

68
g-index

70
all docs

70
docs citations

70
times ranked

12818
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. <i>Lancet, The</i> , 2003, 361, 1149-1158.	13.7	3,420
2	Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. <i>Lancet, The</i> , 2005, 366, 895-906.	13.7	2,662
3	Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. <i>Lancet, The</i> , 2003, 362, 777-781.	13.7	2,584
4	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. <i>Lancet, The</i> , 2003, 362, 767-771.	13.7	1,978
5	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. <i>Lancet, The</i> , 2003, 362, 759-766.	13.7	1,752
6	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. <i>Lancet, The</i> , 2003, 362, 772-776.	13.7	1,623
7	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2006, 28, 88-136.	2.2	1,144
8	Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure. <i>Circulation</i> , 2006, 113, 671-678.	1.6	817
9	Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2008, 29, 1377-1385.	2.2	549
10	Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). <i>Lancet, The</i> , 2005, 366, 907-913.	13.7	314
11	Diastolic Dysfunction in Heart Failure With Preserved Systolic Function: Need for Objective Evidence. <i>Journal of the American College of Cardiology</i> , 2007, 49, 687-694.	2.8	268
12	Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and design. <i>Journal of Cardiac Failure</i> , 1999, 5, 276-282.	1.7	260
13	Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure. <i>Circulation</i> , 2007, 115, 3111-3120.	1.6	235
14	Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure. <i>Circulation</i> , 2006, 113, 986-994.	1.6	229
15	Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM—Preserved. <i>European Journal of Heart Failure</i> , 2014, 16, 33-40.	7.1	186
16	Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2008, 29, 2641-2650.	2.2	164
17	Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. <i>European Heart Journal</i> , 2006, 27, 2982-2988.	2.2	146
18	Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , 2011, 162, 900-906.	2.7	143

#	ARTICLE	IF	CITATIONS
19	factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. <i>Clinical Cardiology</i> , 2001, 24, 238-244.	1.8	122
20	Theophylline antagonizes cardiovascular responses to dipyridamole in man without affecting increases in plasma adenosine. <i>Acta Physiologica Scandinavica</i> , 1984, 121, 165-171.	2.2	110
21	Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)â€“Added trial. <i>American Heart Journal</i> , 2006, 151, 985-991.	2.7	102
22	The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. <i>Journal of Hypertension</i> , 2008, 26, 2103-2111.	0.5	98
23	The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. <i>European Heart Journal</i> , 2008, 29, 499-508.	2.2	83
24	Impact of Candesartan on Nonfatal Myocardial Infarction and Cardiovascular Death in Patients With Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1794.	7.4	66
25	Evaluation of a web-based ECG-interpretation programme for undergraduate medical students. <i>BMC Medical Education</i> , 2008, 8, 25.	2.4	61
26	Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. <i>Diabetes Care</i> , 2009, 32, 915-920.	8.6	61
27	Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. <i>European Journal of Heart Failure</i> , 2010, 12, 557-565.	7.1	59
28	Associations Between Crowding and Ten-Day Mortality Among Patients Allocated Lower Triage Acuity Levels Without Need of Acute Hospital Care on Departure From the Emergency Department. <i>Annals of Emergency Medicine</i> , 2019, 74, 345-356.	0.6	51
29	Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH Study. <i>Blood Pressure</i> , 2008, 17, 7-17.	1.5	49
30	Prevalence and prognostic impact of bundle branch block in patients with heart failure: Evidence from the CHARM programme. <i>European Journal of Heart Failure</i> , 2007, 9, 510-517.	7.1	47
31	Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program. <i>Journal of the American College of Cardiology</i> , 2008, 52, 2000-2007.	2.8	42
32	Physiciansâ€™ and nursesâ€™ perceptions of patient safety risks in the emergency department. <i>International Emergency Nursing</i> , 2017, 33, 14-19.	1.5	42
33	Contributing factors to errors in Swedish emergency departments. <i>International Emergency Nursing</i> , 2015, 23, 156-161.	1.5	36
34	Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2005, 27, 1447-1458.	2.2	35
35	High beat-to-beat blood pressure variability in atrial fibrillation compared to sinus rhythm. <i>Blood Pressure</i> , 2018, 27, 249-255.	1.5	34
36	Review: From Hypertension to Heart Failure â€” Are There Better Primary Prevention Strategies?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006, 7, 64-73.	1.7	33

#	ARTICLE	IF	CITATIONS
37	Renin-angiotensin-system blockade in the prevention of diabetes. <i>Diabetes Research and Clinical Practice</i> , 2007, 76, S13-S21.	2.8	28
38	Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease. <i>Annals of Medicine</i> , 2012, 44, 262-270.	3.8	26
39	Does individual learning styles influence the choice to use a web-based ECG learning programme in a blended learning setting?. <i>BMC Medical Education</i> , 2012, 12, 5.	2.4	25
40	Skin capillary blood cell velocity in patients with arterial obliterative disease and polycythaemia: a disturbed reactive hyperaemia response. <i>Clinical Physiology</i> , 1985, 5, 35-43.	0.7	24
41	Regression of Left Ventricular Mass with Captopril and Metoprolol, and the Effects on Glucose and Lipid Metabolism. <i>Blood Pressure</i> , 2001, 10, 101-110.	1.5	24
42	Impact of Cigarette Smoking in High-Risk Patients Participating in a Clinical Trial. A Substudy from the Heart Outcomes Prevention Evaluation (HOPE) Trial. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005, 12, 75-81.	2.8	24
43	Effect of intravenous magnesium on heart rate and heart rate variability in patients with chronic atrial fibrillation. <i>American Journal of Cardiology</i> , 1999, 84, 104-108.	1.6	20
44	Plasma NT-proBNP concentration is related to ambulatory pulse pressure in peripheral arterial disease. <i>Blood Pressure</i> , 2005, 14, 99-106.	1.5	20
45	Comparison of CNS-Related Subjective Symptoms in Hypertensive Patients Treated with Either a New Controlled Release (CR/ZOK) Formulation of Metoprolol or Atenolol. <i>Journal of Clinical Pharmacology</i> , 1990, 30, S82-90.	2.0	19
46	Videophotometric capillaroscopy for evaluating drug effects on skin microcirculation—a double-blind study with nifedipine. <i>Clinical Physiology</i> , 1984, 4, 169-176.	0.7	17
47	Factors influencing clinicians' perceptions of interruptions as disturbing or non-disturbing: A qualitative study. <i>International Emergency Nursing</i> , 2016, 27, 11-16.	1.5	17
48	Effect of Amlodipine Versus Felodipine Extended Release on 24-Hour Ambulatory Blood Pressure in Hypertension. <i>American Journal of Hypertension</i> , 1998, 11, 690-696.	2.0	14
49	Candesartan for the treatment of hypertension and heart failure. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 1589-1597.	1.8	14
50	Skin microvascular dilatation response to acetylcholine and sodium nitroprusside in peripheral arterial disease. <i>Clinical Physiology and Functional Imaging</i> , 2002, 22, 370-374.	1.2	13
51	Where Are We With the Management of Hypertension? From Science to Clinical Practice. <i>Journal of Clinical Hypertension</i> , 2009, 11, 66-73.	2.0	13
52	Amino-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity C-Reactive Protein but Not Cystatin C Predict Cardiovascular Events in Male Patients with Peripheral Artery Disease Independently of Ambulatory Pulse Pressure. <i>American Journal of Hypertension</i> , 2014, 27, 363-371.	2.0	13
53	Acrodermatitis Chronica Atrophicans Herxheimer Can Often Mimic a Peripheral Vascular Disorder. <i>Acta Medica Scandinavica</i> , 2009, 220, 485-488.	0.0	12
54	Significant changes in emergency department length of stay and case mix over eight years at a large Swedish University Hospital. <i>International Emergency Nursing</i> , 2019, 43, 50-55.	1.5	11

#	ARTICLE	IF	CITATIONS
55	Reasons for interrupting colleagues during emergency department work – A qualitative study. <i>International Emergency Nursing</i> , 2016, 29, 21-26.	1.5	9
56	Ambulatory pulse pressure predicts cardiovascular events in patients with peripheral arterial disease. <i>Blood Pressure</i> , 2012, 21, 227-232.	1.5	8
57	Systolic blood pressure increases in patients with atrial fibrillation regaining sinus rhythm after electrical cardioversion. <i>Journal of Clinical Hypertension</i> , 2019, 21, 363-368.	2.0	8
58	Angiotensin receptor blockers in heart failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003, 4, 171-175.	1.7	5
59	Change in blood pressure during hospitalisation for acute heart failure predicts mortality. <i>Scandinavian Cardiovascular Journal</i> , 2010, 44, 325-330.	1.2	5
60	Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study. <i>Blood Pressure</i> , 2012, 21, 82-87.	1.5	4
61	Amlodipine+Benazepril is Superior to Hydrochlorothiazide+Benazepril Irrespective of Baseline Pulse Pressure: Subanalysis of the ACCOMPLISH Trial. <i>Journal of Clinical Hypertension</i> , 2015, 17, 141-146.	2.0	4
62	Corrigendum to –Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to ÅCHARM-Preserved™ [Eur J Heart Fail2014;16:33-40]. <i>European Journal of Heart Failure</i> , 2014, 16, 592-592.	7.1	3
63	Ambulatory blood pressure monitoring and blood pressure control in patients with coronary artery disease – A randomized controlled trial. <i>International Journal of Cardiology: Hypertension</i> , 2021, 8, 100074.	2.2	3
64	Adrenaline Responsiveness in Mild Hypertension: No Evidence for Altered Å ² -Adrenoceptor Sensitivity. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 32, 753-759.	1.9	3
65	Why Medical Students Choose to Use or Not to Use a Web-Based Electrocardiogram Learning Resource: Mixed Methods Study. <i>JMIR Medical Education</i> , 2019, 5, e12791.	2.6	3
66	Changes in 24-h ambulatory blood pressure following restoration of sinus rhythm in patients with atrial fibrillation. <i>Journal of Hypertension</i> , 2021, 39, 243-249.	0.5	3
67	Myocardial ischaemia in patients with peripheral arterial disease. <i>Clinical Physiology and Functional Imaging</i> , 2007, 27, 30-35.	1.2	1
68	Improvement of blood pressure control and physicians' management over time in patients with coronary artery disease. <i>Blood Pressure</i> , 2016, 25, 286-291.	1.5	1
69	Urokinase reduced the need for open surgical procedures in acute ischemia of the leg. <i>Evidence-based Cardiovascular Medicine</i> , 1998, 2, 82.	0.0	0